This report serves to describe the mutational landscape and properties of a given individual set, as well as rank genes and genesets according to mutational significance. MutSig v1.5 was used to generate the results found in this report.
-
Working with individual set: TGCT-TP
-
Number of patients in set: 149
The input for this pipeline is a set of individuals with the following files associated for each:
-
An annotated .maf file describing the mutations called for the respective individual, and their properties.
-
A .wig file that contains information about the coverage of the sample.
-
MAF used for this analysis:TGCT-TP.final_analysis_set.maf
-
Blacklist used for this analysis: pancan_mutation_blacklist.v14.hg19.txt
-
Significantly mutated genes (q ≤ 0.1): 47
-
Mutations seen in COSMIC: 76
-
Significantly mutated genes in COSMIC territory: 4
-
Significantly mutated genesets: 2
-
Significantly mutated genesets: (excluding sig. mutated genes):0
-
Read 149 MAFs of type "Baylor-Illumina"
-
Total number of mutations in input MAFs: 14126
-
After removing 55 mutations outside chr1-24: 14071
-
After removing 470 blacklisted mutations: 13601
-
After removing 2025 noncoding mutations: 11576
-
After collapsing adjacent/redundant mutations: 11575
-
Number of mutations before filtering: 11575
-
After removing 854 mutations outside gene set: 10721
-
After removing 8 mutations outside category set: 10713
type | count |
---|---|
Frame_Shift_Del | 202 |
Frame_Shift_Ins | 94 |
In_Frame_Del | 99 |
In_Frame_Ins | 23 |
Missense_Mutation | 6945 |
Nonsense_Mutation | 463 |
Silent | 2704 |
Splice_Site | 170 |
Translation_Start_Site | 13 |
Total | 10713 |
category | n | N | rate | rate_per_mb | relative_rate | exp_ns_s_ratio |
---|---|---|---|---|---|---|
*CpG->(A/T) | 1608 | 277176689 | 5.8e-06 | 5.8 | 3.5 | 2.1 |
*Cp(A/C/T)->(A/T) | 3534 | 2192395219 | 1.6e-06 | 1.6 | 0.97 | 2.7 |
A->(C/G) | 1087 | 2336356068 | 4.7e-07 | 0.47 | 0.28 | 3.4 |
flip | 725 | 4805927976 | 1.5e-07 | 0.15 | 0.091 | 5.3 |
indel+null | 1048 | 4805927976 | 2.2e-07 | 0.22 | 0.13 | NaN |
double_null | 7 | 4805927976 | 1.5e-09 | 0.0015 | 0.00087 | NaN |
Total | 8009 | 4805927976 | 1.7e-06 | 1.7 | 1 | 3.5 |
The x axis represents the samples. The y axis represents the exons, one row per exon, and they are sorted by average coverage across samples. For exons with exactly the same average coverage, they are sorted next by the %GC of the exon. (The secondary sort is especially useful for the zero-coverage exons at the bottom). If the figure is unpopulated, then full coverage is assumed (e.g. MutSig CV doesn't use WIGs and assumes full coverage).
The mutation spectrum is depicted in the lego plots below in which the 96 possible mutation types are subdivided into six large blocks, color-coded to reflect the base substitution type. Each large block is further subdivided into the 16 possible pairs of 5' and 3' neighbors, as listed in the 4x4 trinucleotide context legend. The height of each block corresponds to the mutation frequency for that kind of mutation (counts of mutations normalized by the base coverage in a given bin). The shape of the spectrum is a signature for dominant mutational mechanisms in different tumor types.
Column Descriptions:
-
N = number of sequenced bases in this gene across the individual set
-
n = number of (nonsilent) mutations in this gene across the individual set
-
npat = number of patients (individuals) with at least one nonsilent mutation
-
nsite = number of unique sites having a non-silent mutation
-
nsil = number of silent mutations in this gene across the individual set
-
n1 = number of nonsilent mutations of type: *CpG->(A/T)
-
n2 = number of nonsilent mutations of type: *Cp(A/C/T)->(A/T)
-
n3 = number of nonsilent mutations of type: A->(C/G)
-
n4 = number of nonsilent mutations of type: flip
-
n5 = number of nonsilent mutations of type: indel+null
-
n6 = number of nonsilent mutations of type: double_null
-
p_ns_s = p-value for the observed nonsilent/silent ratio being elevated in this gene
-
p = p-value (overall)
-
q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)
rank | gene | description | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p_ns_s | p | q |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | KRAS | v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog | 105343 | 19 | 19 | 7 | 0 | 0 | 8 | 3 | 8 | 0 | 0 | 0.029 | 4.2e-15 | 3.3e-11 |
2 | KIT | v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog | 449194 | 27 | 26 | 13 | 0 | 0 | 5 | 8 | 13 | 1 | 0 | 0.0034 | 5.2e-15 | 3.3e-11 |
3 | ANKLE1 | ankyrin repeat and LEM domain containing 1 | 210372 | 12 | 12 | 7 | 0 | 0 | 0 | 1 | 0 | 11 | 0 | 0.72 | 5.3e-15 | 3.3e-11 |
4 | FAM104B | family with sequence similarity 104, member B | 48754 | 11 | 7 | 3 | 0 | 0 | 1 | 0 | 5 | 5 | 0 | 0.15 | 1.9e-14 | 9.1e-11 |
5 | NRAS | neuroblastoma RAS viral (v-ras) oncogene homolog | 87314 | 7 | 7 | 4 | 0 | 0 | 3 | 4 | 0 | 0 | 0 | 0.14 | 5.4e-11 | 2e-07 |
6 | MUC4 | mucin 4, cell surface associated | 539634 | 27 | 20 | 25 | 5 | 2 | 15 | 5 | 5 | 0 | 0 | 0.12 | 2.5e-09 | 7.8e-06 |
7 | PNPLA4 | patatin-like phospholipase domain containing 4 | 116976 | 5 | 5 | 1 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0.27 | 6e-08 | 0.00016 |
8 | DDX11 | DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 11 (CHL1-like helicase homolog, S. cerevisiae) | 450278 | 8 | 8 | 4 | 1 | 1 | 2 | 0 | 2 | 3 | 0 | 0.57 | 1.6e-07 | 0.00035 |
9 | PRSS3 | protease, serine, 3 | 138001 | 7 | 6 | 4 | 1 | 1 | 5 | 0 | 0 | 1 | 0 | 0.35 | 1.7e-07 | 0.00035 |
10 | MUC6 | mucin 6, oligomeric mucus/gel-forming | 1077081 | 15 | 15 | 11 | 3 | 1 | 9 | 1 | 4 | 0 | 0 | 0.23 | 3.9e-07 | 0.00072 |
11 | HSF4 | heat shock transcription factor 4 | 184689 | 6 | 6 | 5 | 0 | 2 | 2 | 2 | 0 | 0 | 0 | 0.15 | 6e-07 | 0.001 |
12 | FAM101B | family with sequence similarity 101, member B | 66098 | 4 | 4 | 3 | 0 | 0 | 1 | 2 | 0 | 1 | 0 | 0.3 | 8.3e-07 | 0.0013 |
13 | SP8 | Sp8 transcription factor | 124935 | 6 | 6 | 1 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0.052 | 9.5e-07 | 0.0014 |
14 | DEK | DEK oncogene (DNA binding) | 174028 | 5 | 5 | 2 | 0 | 0 | 1 | 0 | 4 | 0 | 0 | 0.5 | 1.5e-06 | 0.002 |
15 | CDC27 | cell division cycle 27 homolog (S. cerevisiae) | 359494 | 6 | 6 | 4 | 1 | 0 | 1 | 1 | 0 | 4 | 0 | 0.39 | 1.7e-06 | 0.002 |
16 | ERC1 | ELKS/RAB6-interacting/CAST family member 1 | 509509 | 7 | 7 | 3 | 0 | 1 | 0 | 5 | 1 | 0 | 0 | 0.17 | 1.8e-06 | 0.002 |
17 | RAC1 | ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1) | 92618 | 4 | 4 | 3 | 0 | 1 | 0 | 1 | 2 | 0 | 0 | 0.32 | 2.2e-06 | 0.0024 |
18 | PCMTD1 | protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1 | 162374 | 6 | 5 | 5 | 0 | 0 | 4 | 2 | 0 | 0 | 0 | 0.24 | 2.4e-06 | 0.0025 |
19 | FANK1 | fibronectin type III and ankyrin repeat domains 1 | 159300 | 4 | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0.34 | 1e-05 | 0.01 |
20 | CSGALNACT2 | chondroitin sulfate N-acetylgalactosaminyltransferase 2 | 246792 | 5 | 5 | 2 | 0 | 0 | 2 | 0 | 0 | 3 | 0 | 0.27 | 0.000012 | 0.011 |
21 | RHPN2 | rhophilin, Rho GTPase binding protein 2 | 294827 | 6 | 6 | 3 | 1 | 1 | 5 | 0 | 0 | 0 | 0 | 0.26 | 0.000013 | 0.011 |
22 | KRTAP1-1 | keratin associated protein 1-1 | 80162 | 3 | 3 | 1 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0.51 | 0.000014 | 0.011 |
23 | NBPF10 | neuroblastoma breakpoint family, member 10 | 911116 | 7 | 7 | 2 | 0 | 0 | 0 | 0 | 7 | 0 | 0 | 0.36 | 0.000014 | 0.011 |
24 | BCL11B | B-cell CLL/lymphoma 11B (zinc finger protein) | 251714 | 5 | 5 | 3 | 0 | 1 | 1 | 0 | 3 | 0 | 0 | 0.24 | 0.000018 | 0.014 |
25 | ATXN3 | ataxin 3 | 168326 | 4 | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 1 | 2e-05 | 0.015 |
26 | PSMD11 | proteasome (prosome, macropain) 26S subunit, non-ATPase, 11 | 196820 | 4 | 4 | 1 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0.21 | 0.000032 | 0.023 |
27 | RFC3 | replication factor C (activator 1) 3, 38kDa | 171015 | 4 | 4 | 2 | 0 | 0 | 2 | 0 | 2 | 0 | 0 | 0.45 | 0.000033 | 0.023 |
28 | GSX2 | GS homeobox 2 | 120709 | 4 | 4 | 4 | 0 | 2 | 0 | 1 | 0 | 1 | 0 | 0.29 | 0.000038 | 0.025 |
29 | CRB2 | crumbs homolog 2 (Drosophila) | 386259 | 6 | 6 | 6 | 0 | 1 | 4 | 1 | 0 | 0 | 0 | 0.12 | 0.000039 | 0.025 |
30 | CCDC64 | coiled-coil domain containing 64 | 235995 | 5 | 5 | 5 | 0 | 1 | 3 | 0 | 0 | 1 | 0 | 0.14 | 0.000053 | 0.033 |
31 | C22orf43 | chromosome 22 open reading frame 43 | 109952 | 3 | 3 | 1 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0.42 | 0.000054 | 0.033 |
32 | CNNM1 | cyclin M1 | 314936 | 5 | 5 | 5 | 0 | 3 | 0 | 1 | 0 | 1 | 0 | 0.17 | 0.000062 | 0.036 |
33 | SERINC2 | serine incorporator 2 | 202282 | 4 | 4 | 2 | 0 | 0 | 1 | 3 | 0 | 0 | 0 | 0.48 | 0.000071 | 0.04 |
34 | ZNRF3 | zinc and ring finger 3 | 317322 | 6 | 6 | 5 | 0 | 2 | 4 | 0 | 0 | 0 | 0 | 0.094 | 0.000072 | 0.04 |
35 | TAS1R3 | taste receptor, type 1, member 3 | 313736 | 5 | 5 | 5 | 1 | 2 | 1 | 1 | 0 | 1 | 0 | 0.52 | 8e-05 | 0.041 |
In this analysis, COSMIC is used as a filter to increase power by restricting the territory of each gene. Cosmic version: v48.
rank | gene | description | n | cos | n_cos | N_cos | cos_ev | p | q |
---|---|---|---|---|---|---|---|---|---|
1 | NRAS | neuroblastoma RAS viral (v-ras) oncogene homolog | 7 | 33 | 7 | 4917 | 7705 | 7.5e-14 | 2.7e-10 |
2 | KRAS | v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog | 19 | 52 | 19 | 7748 | 117424 | 1.2e-13 | 2.7e-10 |
3 | KIT | v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog | 27 | 240 | 27 | 35760 | 10702 | 5.2e-13 | 7.8e-10 |
4 | PIK3CA | phosphoinositide-3-kinase, catalytic, alpha polypeptide | 3 | 220 | 3 | 32780 | 1335 | 0.000026 | 0.03 |
5 | AVPR2 | arginine vasopressin receptor 2 (nephrogenic diabetes insipidus) | 1 | 1 | 1 | 149 | 0 | 0.00025 | 0.1 |
6 | CCNL2 | cyclin L2 | 1 | 1 | 1 | 149 | 1 | 0.00025 | 0.1 |
7 | FAAH | fatty acid amide hydrolase | 1 | 1 | 1 | 149 | 1 | 0.00025 | 0.1 |
8 | LYPLA1 | lysophospholipase I | 1 | 1 | 1 | 149 | 1 | 0.00025 | 0.1 |
9 | MAP3K7 | mitogen-activated protein kinase kinase kinase 7 | 1 | 1 | 1 | 149 | 1 | 0.00025 | 0.1 |
10 | PTK7 | PTK7 protein tyrosine kinase 7 | 1 | 1 | 1 | 149 | 1 | 0.00025 | 0.1 |
Note:
n - number of (nonsilent) mutations in this gene across the individual set.
cos = number of unique mutated sites in this gene in COSMIC
n_cos = overlap between n and cos.
N_cos = number of individuals times cos.
cos_ev = total evidence: number of reports in COSMIC for mutations seen in this gene.
p = p-value for seeing the observed amount of overlap in this gene)
q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)
rank | geneset | description | genes | N_genes | mut_tally | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p_ns_s | p | q |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | BADPATHWAY | When phosphorylated, BAD is inhibited by sequestration; when non-phosphorylated, it promotes apoptosis by inactivating pro-survival BCL-XL and BCL-2. | ADCY1, AKT1, BAD, BAX, BCL2, BCL2L1, CSF2RB, IGF1, IGF1R, IL3, IL3RA, KIT, KITLG, PIK3CA, PIK3R1, PRKACB, PRKACG, PRKAR1A, PRKAR1B, PRKAR2A, PRKAR2B, YWHAH | 22 | BCL2L1(1), IL3RA(1), KIT(27), PIK3CA(3), PIK3R1(1), PRKAR2B(2) | 5007558 | 35 | 32 | 20 | 5 | 0 | 10 | 9 | 15 | 1 | 0 | 0.11 | 1.1e-06 | 0.0007 |
2 | CDC42RACPATHWAY | PI3 kinase stimulates cell migration by activating cdc42, which activates ARP2/3, which in turn promotes formation of new actin fibers. | ACTR2, ACTR3, ARHA, ARPC1A, ARPC1B, ARPC2, ARPC3, ARPC4, CDC42, PAK1, PDGFRA, PIK3CA, PIK3R1, RAC1, WASL | 14 | ARPC1B(1), ARPC2(1), PAK1(1), PDGFRA(1), PIK3CA(3), PIK3R1(1), RAC1(4), WASL(2) | 3047557 | 14 | 14 | 12 | 0 | 2 | 7 | 2 | 3 | 0 | 0 | 0.025 | 0.00015 | 0.045 |
3 | NKCELLSPATHWAY | Natural killer (NK) lymphocytes are inhibited by MHC and activated by surface glycoproteins on tumor or virus-infected cells, which undergo perforin-mediated lysis. | B2M, HLA-A, IL18, ITGB1, KLRC1, KLRC2, KLRC3, KLRC4, KLRD1, LAT, MAP2K1, MAPK3, PAK1, PIK3CA, PIK3R1, PTK2B, PTPN6, RAC1, SYK, VAV1 | 20 | HLA-A(1), KLRC3(2), KLRC4(1), PAK1(1), PIK3CA(3), PIK3R1(1), PTK2B(1), RAC1(4), SYK(1), VAV1(2) | 4322569 | 17 | 16 | 15 | 0 | 3 | 7 | 3 | 4 | 0 | 0 | 0.0088 | 0.0007 | 0.14 |
4 | SALMONELLAPATHWAY | Salmonella induces membrane ruffling in infected cells via bacterial proteins including SipA, SipC, and SopE, which alter actin structure. | ACTA1, ACTR2, ACTR3, ARPC1A, ARPC1B, ARPC2, ARPC3, ARPC4, CDC42, RAC1, WASF1, WASL | 12 | ACTA1(1), ARPC1B(1), ARPC2(1), RAC1(4), WASL(2) | 1876385 | 9 | 9 | 8 | 0 | 1 | 4 | 2 | 2 | 0 | 0 | 0.089 | 0.0029 | 0.44 |
5 | RASPATHWAY | Ras activation stimulates many signaling cascades, including PI3K/AKT activation to inhibit apoptosis. | AKT1, ARHA, BAD, BCL2L1, CASP9, CDC42, CHUK, ELK1, H2AFX, HRAS, MAP2K1, MAPK3, MLLT7, NFKB1, PIK3CA, PIK3R1, RAC1, RAF1, RALA, RALBP1, RALGDS, RELA, RHOA | 21 | BCL2L1(1), HRAS(1), PIK3CA(3), PIK3R1(1), RAC1(4), RAF1(1), RALGDS(1), RELA(1), RHOA(1) | 4462015 | 14 | 14 | 12 | 1 | 2 | 5 | 2 | 3 | 2 | 0 | 0.075 | 0.0039 | 0.48 |
6 | HSA04662_B_CELL_RECEPTOR_SIGNALING_PATHWAY | Genes involved in B cell receptor signaling pathway | AKT1, AKT2, AKT3, BCL10, BLNK, BTK, CARD11, CD19, CD22, CD72, CD79A, CD79B, CD81, CHP, CHUK, CR2, FCGR2B, FOS, GSK3B, HRAS, IFITM1, IKBKB, IKBKG, INPP5D, JUN, KRAS, LILRB3, LYN, MALT1, NFAT5, NFATC1, NFATC2, NFATC3, NFATC4, NFKB1, NFKB2, NFKBIA, NFKBIB, NFKBIE, NRAS, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PIK3R3, PIK3R5, PLCG2, PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2, PRKCB1, PTPN6, RAC1, RAC2, RAC3, RASGRP3, SYK, VAV1, VAV2, VAV3 | 63 | AKT3(1), BLNK(1), BTK(1), CARD11(1), CD19(1), CD79A(1), CD79B(1), FOS(2), HRAS(1), INPP5D(1), KRAS(19), MALT1(1), NFATC2(4), NFATC4(1), NFKB2(2), NFKBIB(1), NRAS(7), PIK3CA(3), PIK3CB(2), PIK3CD(4), PIK3R1(1), PIK3R5(1), PPP3R2(1), RAC1(4), SYK(1), VAV1(2), VAV3(1) | 17419085 | 66 | 52 | 48 | 9 | 8 | 32 | 12 | 13 | 1 | 0 | 0.0035 | 0.0054 | 0.55 |
7 | NUCLEOTIDE_METABOLISM | ADSL, ADSS, DHFR, HPRT1, IMPDH1, MTHFD2, NME2, OAZ1, POLA, POLB, POLD1, POLG, PRPS2, RRM1, SAT, SRM | 14 | ADSL(2), ADSS(3), DHFR(1), POLB(1), POLD1(2), POLG(2) | 2969192 | 11 | 11 | 11 | 1 | 5 | 5 | 1 | 0 | 0 | 0 | 0.09 | 0.019 | 1 | |
8 | HSA04664_FC_EPSILON_RI_SIGNALING_PATHWAY | Genes involved in Fc epsilon RI signaling pathway | AKT1, AKT2, AKT3, BTK, CSF2, FCER1A, FCER1G, FYN, GAB2, GRB2, HRAS, IL13, IL3, IL4, IL5, INPP5D, KRAS, LAT, LCP2, LYN, MAP2K1, MAP2K2, MAP2K3, MAP2K4, MAP2K6, MAP2K7, MAPK1, MAPK10, MAPK11, MAPK12, MAPK13, MAPK14, MAPK3, MAPK8, MAPK9, MS4A2, NRAS, PDK1, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PIK3R3, PIK3R5, PLA2G10, PLA2G12A, PLA2G12B, PLA2G1B, PLA2G2A, PLA2G2D, PLA2G2E, PLA2G2F, PLA2G3, PLA2G4A, PLA2G5, PLA2G6, PLCG1, PLCG2, PRKCA, PRKCB1, PRKCD, PRKCE, RAC1, RAC2, RAC3, RAF1, SOS1, SOS2, SYK, TNF, VAV1, VAV2, VAV3 | 73 | AKT3(1), BTK(1), HRAS(1), INPP5D(1), KRAS(19), LCP2(1), MAP2K2(1), MAPK10(1), MAPK11(1), NRAS(7), PIK3CA(3), PIK3CB(2), PIK3CD(4), PIK3R1(1), PIK3R5(1), PLA2G6(1), RAC1(4), RAF1(1), SOS1(3), SYK(1), VAV1(2), VAV3(1) | 16388160 | 58 | 48 | 40 | 8 | 7 | 24 | 12 | 14 | 1 | 0 | 0.011 | 0.02 | 1 |
9 | SETPATHWAY | Cytotoxic T cells release perforin, which to allow entry into target cells of granzyme B, which activates caspases, and granzyme A, which induces caspase-independent apoptosis. | ANP32A, APEX1, CREBBP, DFFA, DFFB, GZMA, GZMB, HMGB2, NME1, PRF1, SET | 11 | APEX1(1), CREBBP(6), DFFB(1), SET(1) | 2382845 | 9 | 9 | 9 | 0 | 0 | 7 | 1 | 0 | 1 | 0 | 0.082 | 0.02 | 1 |
10 | NGFPATHWAY | Nerve growth factor (NGF) stimulates neural survival and proliferation via the TrkA and p75 receptors, which induce DAG and IP3 production and activate Ras. | CSNK2A1, DPM2, ELK1, FOS, GRB2, HRAS, JUN, KLK2, MAP2K1, MAPK3, MAPK8, NGFB, NGFR, PIK3CA, PIK3R1, PLCG1, RAF1, SHC1, SOS1 | 18 | CSNK2A1(1), FOS(2), HRAS(1), KLK2(1), NGFR(1), PIK3CA(3), PIK3R1(1), RAF1(1), SOS1(3) | 4359991 | 14 | 13 | 13 | 1 | 2 | 7 | 2 | 2 | 1 | 0 | 0.088 | 0.028 | 1 |
rank | geneset | description | genes | N_genes | mut_tally | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p_ns_s | p | q |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | CDC42RACPATHWAY | PI3 kinase stimulates cell migration by activating cdc42, which activates ARP2/3, which in turn promotes formation of new actin fibers. | ACTR2, ACTR3, ARHA, ARPC1A, ARPC1B, ARPC2, ARPC3, ARPC4, CDC42, PAK1, PDGFRA, PIK3CA, PIK3R1, RAC1, WASL | 13 | ARPC1B(1), ARPC2(1), PAK1(1), PDGFRA(1), PIK3CA(3), PIK3R1(1), WASL(2) | 2954939 | 10 | 10 | 9 | 0 | 1 | 7 | 1 | 1 | 0 | 0 | 0.067 | 0.014 | 1 |
2 | NUCLEOTIDE_METABOLISM | ADSL, ADSS, DHFR, HPRT1, IMPDH1, MTHFD2, NME2, OAZ1, POLA, POLB, POLD1, POLG, PRPS2, RRM1, SAT, SRM | 14 | ADSL(2), ADSS(3), DHFR(1), POLB(1), POLD1(2), POLG(2) | 2969192 | 11 | 11 | 11 | 1 | 5 | 5 | 1 | 0 | 0 | 0 | 0.09 | 0.019 | 1 | |
3 | SETPATHWAY | Cytotoxic T cells release perforin, which to allow entry into target cells of granzyme B, which activates caspases, and granzyme A, which induces caspase-independent apoptosis. | ANP32A, APEX1, CREBBP, DFFA, DFFB, GZMA, GZMB, HMGB2, NME1, PRF1, SET | 11 | APEX1(1), CREBBP(6), DFFB(1), SET(1) | 2382845 | 9 | 9 | 9 | 0 | 0 | 7 | 1 | 0 | 1 | 0 | 0.082 | 0.02 | 1 |
4 | NKCELLSPATHWAY | Natural killer (NK) lymphocytes are inhibited by MHC and activated by surface glycoproteins on tumor or virus-infected cells, which undergo perforin-mediated lysis. | B2M, HLA-A, IL18, ITGB1, KLRC1, KLRC2, KLRC3, KLRC4, KLRD1, LAT, MAP2K1, MAPK3, PAK1, PIK3CA, PIK3R1, PTK2B, PTPN6, RAC1, SYK, VAV1 | 19 | HLA-A(1), KLRC3(2), KLRC4(1), PAK1(1), PIK3CA(3), PIK3R1(1), PTK2B(1), SYK(1), VAV1(2) | 4229951 | 13 | 12 | 12 | 0 | 2 | 7 | 2 | 2 | 0 | 0 | 0.023 | 0.028 | 1 |
5 | NGFPATHWAY | Nerve growth factor (NGF) stimulates neural survival and proliferation via the TrkA and p75 receptors, which induce DAG and IP3 production and activate Ras. | CSNK2A1, DPM2, ELK1, FOS, GRB2, HRAS, JUN, KLK2, MAP2K1, MAPK3, MAPK8, NGFB, NGFR, PIK3CA, PIK3R1, PLCG1, RAF1, SHC1, SOS1 | 18 | CSNK2A1(1), FOS(2), HRAS(1), KLK2(1), NGFR(1), PIK3CA(3), PIK3R1(1), RAF1(1), SOS1(3) | 4359991 | 14 | 13 | 13 | 1 | 2 | 7 | 2 | 2 | 1 | 0 | 0.088 | 0.028 | 1 |
6 | ERK5PATHWAY | Signaling between a tissue and its innervating axon stimulates retrograde transport via Trk receptors, which activate Erk5, which induces transcription of anti-apoptotic factors. | AKT1, CREB1, GRB2, HRAS, MAPK1, MAPK3, MAPK7, MEF2A, MEF2B, MEF2C, MEF2D, NTRK1, PIK3CA, PIK3R1, PLCG1, RPS6KA1, SHC1 | 17 | HRAS(1), MAPK7(3), MEF2A(3), MEF2B(1), MEF2C(1), NTRK1(1), PIK3CA(3), PIK3R1(1), RPS6KA1(2) | 4532448 | 16 | 16 | 12 | 2 | 4 | 10 | 0 | 1 | 1 | 0 | 0.076 | 0.032 | 1 |
7 | SA_PTEN_PATHWAY | PTEN is a tumor suppressor that dephosphorylates the lipid messenger phosphatidylinositol triphosphate. | AKT1, AKT2, AKT3, BPNT1, GRB2, ILK, MAPK1, MAPK3, PDK1, PIK3CA, PIK3CD, PIP3-E, PTEN, PTK2B, RBL2, SHC1, SOS1 | 16 | AKT3(1), ILK(1), PIK3CA(3), PIK3CD(4), PTK2B(1), RBL2(1), SOS1(3) | 4601358 | 14 | 12 | 12 | 1 | 2 | 6 | 3 | 2 | 1 | 0 | 0.1 | 0.037 | 1 |
8 | IFNAPATHWAY | Interferon alpha, active in the immune response, binds to the IFN receptor and activates Jak1 and Tyk2, which phosphorylate Stat1 and Stat2. | IFNA1, IFNAR1, IFNAR2, IFNB1, ISGF3G, JAK1, STAT1, STAT2, TYK2 | 8 | IFNAR1(1), IFNAR2(1), JAK1(1), STAT1(2), TYK2(3) | 2481181 | 8 | 8 | 8 | 0 | 1 | 5 | 1 | 0 | 1 | 0 | 0.098 | 0.038 | 1 |
9 | BILE_ACID_BIOSYNTHESIS | ACAA1, ACAA2, ADH1A, ADH1A, ADH1B, ADH1C, ADH1B, ADH1C, ADH4, ADH6, ADH7, ADHFE1, AKR1C4, AKR1D1, ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1, ALDH2, ALDH3A1, ALDH3A2, ALDH9A1, BAAT, CEL, CYP27A1, CYP7A1, HADHB, SOAT2, SRD5A1, SRD5A2 | 27 | ADH1B(1), ADH4(1), AKR1C4(1), ALDH1A1(1), ALDH1B1(1), ALDH3A1(2), BAAT(2), CEL(3), CYP7A1(2), SOAT2(1) | 5259287 | 15 | 14 | 15 | 1 | 4 | 10 | 0 | 1 | 0 | 0 | 0.035 | 0.039 | 1 | |
10 | HSA00660_C5_BRANCHED_DIBASIC_ACID_METABOLISM | Genes involved in C5-branched dibasic acid metabolism | ILVBL, SUCLA2 | 2 | ILVBL(3) | 495479 | 3 | 3 | 3 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0.36 | 0.041 | 1 |
In brief, we tabulate the number of mutations and the number of covered bases for each gene. The counts are broken down by mutation context category: four context categories that are discovered by MutSig, and one for indel and 'null' mutations, which include indels, nonsense mutations, splice-site mutations, and non-stop (read-through) mutations. For each gene, we calculate the probability of seeing the observed constellation of mutations, i.e. the product P1 x P2 x ... x Pm, or a more extreme one, given the background mutation rates calculated across the dataset. [1]
In addition to the links below, the full results of the analysis summarized in this report can also be downloaded programmatically using firehose_get, or interactively from either the Broad GDAC website or TCGA Data Coordination Center Portal.